1-4 of 4
Kathy J Gratton
Close
Sort by
Journal Articles

A miRNA Risk Score for the Prediction of Response to Lenalidomide in Multiple Myeloma (MM) Patients

Paola Neri, MD, PhD, Andrew R Belch, MD, Jordan Johnson, Kathy J Gratton, Li Ren, PhD, Peter Duggan, MD, FRCPC, Adnan Mansoor, MD, FCPS, FRCP(C), FCAP, Douglas A. Stewart, MD, FRCP, Nizar Bahlis, MD
Journal: Blood
Blood (2011) 118 (21): 987.
https://doi.org/10.1182/blood.V118.21.987.987
Published: 2011
Journal Articles

Mir-34a Sensitizes Multiple Myeloma (MM) Cells to the Proteasome Inhibitor Bortezomib

Erin Stebner, Paola Neri, MD, PhD, Jordan Johnson, Kathy J Gratton, Li Ren, PhD, Peter Duggan, MD, FRCPC, Douglas A. Stewart, MD, FRCP, Nizar Bahlis, MD
Journal: Blood
Blood (2011) 118 (21): 138.
https://doi.org/10.1182/blood.V118.21.138.138
Published: 2011
Journal Articles

Bortezomib Impairs Myeloma Cells (MM) Homologous Recombination Through Inhibition of the E2-Ubiquitin-Conjugating Enzyme UBC13

Paola Neri, MD, PhD, Li Ren, PhD, Jordan Johnson, Kathy J Gratton, Erin Stebner, Carolyn J Owen, MD, FRCPC, Peter Duggan, MD, FRCPC, Douglas A. Stewart, MD, FRCP, Nizar Bahlis, MD
Journal: Blood
Blood (2011) 118 (21): 1834.
https://doi.org/10.1182/blood.V118.21.1834.1834
Published: 2011
Journal Articles

A miRNA Risk Score for the Prediction of Response to Rituximab-CHOP Therapy and Survival of Patients with Diffuse Large B-Cell Lymphoma

Nizar J Bahlis, MD, Carolyn J Owen, MD, FRCPC, Paola Neri, MD, PhD, Adnan Mansoor, MD, FCPS, FRCP(C), FCAP, Kathy J Gratton, Peter Duggan, MD, FRCPC, Pietro Ravani, MD, PhD, Douglas A. Stewart, MD, FRCP
Journal: Blood
Blood (2010) 116 (21): 324.
https://doi.org/10.1182/blood.V116.21.324.324
Published: 2010